Background
==========

It is estimated that the incidence of cutaneous basal cell carcinoma is increasing worldwide by up to 10% per year \[[@B1]\] and it currently accounts for approximately 80% of all non-melanoma skin cancer -- with highest rates in elderly men and increasing incidence in young women \[[@B2]\]. Several sub-types of BCC have been identified. These include nodular-ulcerated BCC (the most frequently occurring type; often with ulceration (\"rodent ulcer\")); superficial BCC (often multiple); sclerosing BCC (cancer cells surrounded by dense fibrosis and so resemble scars; highest recurrence rate of BCCs after treatment); cystic BCC (uncommon; tumour undergoes central degradation to form a cystic lesion); linear BCC (recently recognised clinical entity with increased risk for aggressive histopathology); and micronodular BCC (small tumour nests; often with subclinical growth). Although BCC only occasionally (0.003--0.55% of cases \[[@B3]-[@B5]\]), results in metastasis and is seldom fatal, BCC is often locally invasive with destructive growth and may be associated with severe disfigurement and morbidity as a result of local tissue destruction or due to necessary surgery. Furthermore, people with BCC are at higher risks of developing further BCCs and other malignancies, including squamous cell carcinomas, malignant melanomas, and possibly also non-cutaneous malignancies \[[@B1]\].

Current selection of best treatment for BCC is based on accurate diagnosis and sub-classification of these cancers, mainly on histomorphology/pathology of H&E stained sections \[[@B6]\]. Features associated with recurrence and metastasis are also considered -- including tumour diameter \>2 cm, location in the central part of the face or ear, present for long duration, incomplete excision, aggressive growth pattern (based on histology) and perinuclear or perivascular involvement \[[@B2]\]. Genes reported to be associated with susceptibility to BCC include CYP2D6, GST-T1, vitamin D receptor, and TNF; with UVB irradiaton known to cause mutations in the p53 tumour suppressor gene, leading to the development of this cancer \[[@B1]\].

With the exception of a single study of BCCs using a small cDNA microarray -- representing 1,718 genes \[[@B7]\] -- investigations aimed at identifying BCC biomarkers and understanding the molecular events involved in this disease have, in general, been limited to one-at-a-time studies, built on chance analyses of proteins or mRNAs. Examples of such protein analysis have identified CD10 \[[@B8],[@B9]\], p63 \[[@B10]\], low expression levels of CD44 \[[@B11]\] to be associated with the presence of BCC, generally with absence of ICAM-1 and LFA-3 adhesion molecule expression \[[@B12]\] and with Ki67 expression levels differing between BCCs that recur, compared to those that do not recur \[[@B13]\]. RT-PCR analysis has indicated *1,25-dihydroxyvitamin D(3) receptor*mRNA levels to be increased in BCCs compared to normal skin \[[@B14]\], while qPCR quantification of *gli1*transcripts has been found to discriminate BCC (and trichoepithelioma) from other skin cancers \[[@B15]\].

While such studies have indicated the importance and relevance of gene expression analyses in BCC, the number of gene products simultaneously analysed have been very limited. In order to increase our understanding of the molecular events involved in the development/expression of BCC, here we report our findings from whole genome microarray analysis of BCC and normal skin specimens.

Results
=======

Quality Control of Microarray Data
----------------------------------

As indicated in Table [1](#T1){ref-type="table"}, quality control (Q.C.) analysis of all 25 microarray data sets (from 20 BCC and 5 normal skin specimens) indicated an average percentage present call of 42.68% (+/- 5.79 SD). This would be of the order expected for high quality RNA from cell lines from many origins (Affymetrix Inc. \"Genechip^®^Expression Analysis Data Analysis Fundamentals\" \[[@B16]\], indicating that these results are acceptable for further analysis. Again, based on cell line Q.C. parameters, the accepted background levels are \<100, while 52.31 +/- 4.08 was found in this study; acceptable noise levels are \<3, here we report 1.67 +/- 0.4; and the acceptable scaling factor is \<3 fold between data sets being compared. This was generally, but not always, achieved. The acceptable 3\'/M ratio of \<3 was achieved in 18/25 cases.

###### 

Q.C. Analysis of Microarray Results

  **Specimen I.D.**   **Present Call (%)**   **Background**   **Noise**   **Scaling Factor**   **3\'/M Ratio GAPDH**
  ------------------- ---------------------- ---------------- ----------- -------------------- -----------------------
  BCC26               49.9                   52.6             1.82        0.94                 14.56
  JT2                 50.2                   63.6             2.05        0.795                1.41
  JT3                 49.9                   53.85            1.74        1.037                1.27
  BCC4                48.8                   55.72            1.87        0.868                1.82
  JT6                 41.8                   50.33            1.56        2.431                2.46
  JT11                39                     48.93            1.58        3.173                2.17
  JT8                 43                     46.94            1.48        2.463                1.95
  JT9                 46.5                   53.85            1.71        1.434                1.66
  T16                 43.4                   51.87            1.62        1.896                3.25
  JT12                38.1                   53.09            1.7         2.709                2.86
  JT13                47.1                   54.46            1.67        1.374                1.67
  JT4                 46.5                   55.73            1.77        1.18                 1.66
  JT5                 45.8                   53.86            1.75        1.453                1.86
  T24                 38.5                   57.3             1.83        2.905                3.0
  T25                 34.1                   56.57            1.77        3.988                3.1
  T28                 34.3                   56.32            1.79        3.771                3.6
  JT7                 39.6                   48.25            1.56        3.098                2.52
  T11                 43.3                   50.10            1.61        2.416                2.1
  T19                 32.2                   54.24            1.7         4.539                3.1
  T22                 29.1                   49.14            1.59        6.639                5.86
  N1                  46.6                   46.38            1.46        1.571                1.67
  N2                  44.0                   47.85            1.56        1.565                1.8
  N3                  42.5                   50.84            1.63        2.105                2.46
  N5                  46.7                   48.96            1.54        1.417                1.85
  N6                  46.2                   46.92            1.44        1.821                2.39

*Note*: Acceptable Q.C. cut-offs, based on high quality cell line RNA analysis, for background is \<100; noise \<3; scaling factor \<3 fold between specimens being compared; 3\'/M ratio \<3 (Affymetrix Inc. \"Genechip^®^Expression Analysis Data Analysis Fundamentals\" \[16\]).

Data Analysis
-------------

Approximately 7% (3,921/54,675) of the probe sets representing transcripts on the microarray were significantly differentially expressed between BCC and normal skin specimens (Tables [2](#T2){ref-type="table"} &[3](#T3){ref-type="table"}; \[see Additional Files [1](#S1){ref-type="supplementary-material"} &[2](#S2){ref-type="supplementary-material"}\] for further information). The scatter plot of data differentially expressed ≥1.2 fold (Fig. [1](#F1){ref-type="fig"}) indicates an even, normal distribution of data. As shown in Table [4](#T4){ref-type="table"}, of the 2,108 up-regulated by ≥1.2 fold, genes involved in many crucial aspects of cellular biology, including metabolism, transcription, cell cycle regulation, cell adhesion, cell migration, cell proliferation and cell motility were amongst the largest groups of genes affected, while oxidative phosphorylation, lipid metabolism, translation, and apoptosis were among the main categories down-regulated ≥1.2 fold in BCCs compared to normal skin (Table [5](#T5){ref-type="table"}). Of the 748 probesets representing transcripts up-regulated by ≥2 fold, approximately 11 were described as cloned cDNAs, 122 were ESTs, 6 were described as hypothetical genes, and 46 encoded hypothetical proteins. Of the 484 transcripts showing ≥2 fold down-regulation, twenty-five represented hypothetical proteins, 11 cloned cDNAs/RIKENS and 49 ESTs.

###### 

Gene Transcripts significantly up-regulated in BCC compared to normal skin specimens (≥1.2 fold; ≥100; p \< 0.05).

  **probe set**   **gene**                                                                **Accession**   **fold change**   **Difference**   **P value**
  --------------- ----------------------------------------------------------------------- --------------- ----------------- ---------------- -------------
  204697_s\_at    chromogranin A (parathyroid secretory protein 1)                        NM_001275       130.34            2497.11          0.000001
  224590_at       X (inactive)-specific transcript                                        BE644917        69.08             427.18           0.001884
  214218_s\_at    X (inactive)-specific transcript                                        AV699347        62.79             621.31           0.00072
  242964_at       gb:AI421677/DB_XREF=gi:4267608/DB_XREF=tf54a03.x1/CLONE                 AI421677        55.54             730.97           0.000005
  224588_at       X (inactive)-specific transcript                                        AA167449        49.82             2086.08          0.000552
  204913_s\_at    SRY (sex determining region Y)-box 11                                   AI360875        27.92             228.19           0.000224
  1560652_at      gb:AL832136.1/DB_XREF=gi:21732679/TID=Hs2.407141.1/CNT=4                AL832136        26.21             638.38           0.000015
  236029_at       FAT tumor suppressor homolog 3 (Drosophila)                             AI283093        24.03             916.82           0.000015
  214913_at       a disintegrin-like and metalloprotease (reprolysin type)                AB002364        23.97             605.9            0.000002
  220345_at       leucine rich repeat transmembrane neuronal 4                            NM_024993       22.24             270.15           0.0061
  233622_x\_at    Transcribed locus, weakly similar to XP_375099.1 hypothetical protein   AL162077        21.31             105.45           0.005425
  230863_at       gb:R73030/DB_XREF=gi:847062/DB_XREF=yj94c11.s1/CLONE=                   R73030          20.05             292.94           0.029359
  204915_s\_at    SRY (sex determining region Y)-box 11                                   AB028641        19.64             524.92           0.000059
  204424_s\_at    LIM domain only 3 (rhombotin-like 2)                                    AL050152        19.19             1287.59          0.003562
  236407_at       gb:R73518/DB_XREF=gi:847550/DB_XREF=yj93h12.s1/CLONE=                   R73518          18.1              355.25           0.000003
  208025_s\_at    high mobility group AT-hook 2///high mobility group AT-hook 2           NM_003483       17.76             506.18           0.000173
  215311_at       MRNA full length insert cDNA clone EUROIMAGE 21920                      AL109696        17.1              448.46           0.000013
  227671_at       X (inactive)-specific transcript                                        AV646597        16.98             383.7            0.003059
  218638_s\_at    spondin 2, extracellular matrix protein                                 NM_012445       16.91             2992.93          0
  208212_s\_at    anaplastic lymphoma kinase (Ki-1)                                       NM_004304       16.76             835.41           0.000003
  226346_at       gb:AA527151/DB_XREF=gi:2269220/DB_XREF=ni07b08.s1/CLONE                 AA527151        15.34             534.55           0
  204914_s\_at    SRY (sex determining region Y)-box 11                                   AW157202        15.1              310.64           0.000124
  215443_at       thyroid stimulating hormone receptor                                    BE740743        14.95             239.99           0.00019
  240460_at       gb:AI190616/DB_XREF=gi:3741825/DB_XREF=qd38e02.x1/CLONE                 AI190616        14.91             168.09           0.000564
  1562107_at      hypothetical protein MGC14738                                           BC007100        14.73             284.47           0.000263
  213960_at       CDNA FLJ37610 fis, clone BRCOC2011398                                   T87225          14.18             534.88           0.000001
  1565936_a\_at   LIM domain only 3 (rhombotin-like 2)                                    T24091          13.94             162.48           0.001811
  229523_at       gb:N66694/DB_XREF=gi:1218819/DB_XREF=yy71g08.s1/CLONE=                  N66694          13.82             614.51           0.000001
  210055_at       thyroid stimulating hormone receptor                                    BE045816        13.81             181.7            0.000595
  224646_x\_at    gb:BF569051/DB_XREF=gi:11642431/DB_XREF=602184410T1/                    BF569051        13.81             1024.01          0.000261
  207468_s\_at    secreted frizzled-related protein 5                                     NM_003015       13.54             437.41           0.001339
  220518_at       target of Nesh-SH3                                                      NM_024801       13.44             448.75           0.001398
  224997_x\_at    H19, imprinted maternally expressed untranslated mRNA                   AL575306        13.39             1131.86          0.000494
  222940_at       sulfotransferase family 1E, estrogen-preferring, member 1               U55764          13.29             560.15           0.000001
  235795_at       gb:AW088232/DB_XREF=gi:6044037/DB_XREF=xc99c09.x1                       AW088232        13.26             199.49           0.000451
  220090_at       chromosome 1 open reading frame 10                                      NM_016190       12.79             736.69           0.00414
  238584_at       IQ motif containing with AAA domain                                     W52934          12.68             222.06           0.001169
  203878_s\_at    matrix metalloproteinase 11 (stromelysin 3)                             NM_005940       12.23             685.83           0.000417
  1557215_at      Transcribed locus, weakly similar to XP_375935.1 hypothetical protein   AK056212        11.92             262.54           0.003503
  210292_s\_at    protocadherin 11 Y-linked///protocadherin 11 X-linked                   AF332218        11.83             211.94           0.000324
  1558964_at      FAT tumor suppressor homolog 3 (Drosophila)                             AA334950        11.22             280.34           0.000123
  214451_at       transcription factor AP-2 beta (activating enhancer binding protein 2   NM_003221       10.67             2196.21          0
  209816_at       patched homolog (Drosophila)                                            AL044175        10.59             245.97           0.001175
  241617_x\_at    gb:BE961949/DB_XREF=gi:11764352/DB_XREF=601655369R1                     BE961949        10.43             1011             0.000972
  209815_at       Patched homolog (Drosophila)                                            BG054916        10.34             2145.95          0.000007
  230496_at       Hypothetical protein FLJ25477                                           BE046923        10.34             131.12           0.000467
  205372_at       pleiomorphic adenoma gene 1                                             NM_002655       10.1              1069.14          0
  229942_at       gb:AW024890/DB_XREF=gi:5878420/DB_XREF=wu92c11.x1                       AW024890        9.98              1649.01          0
  214297_at       gb:BE857703/DB_XREF=gi:10371993/DB_XREF=7g46a02.x1                      BE857703        9.86              819.59           0.000003
  229669_at       Hypothetical protein LOC339260                                          AA166965        9.83              237.59           0.001318

Top 50 transcripts -- based on fold difference are shown (complete list is supplied as supplementary material).

###### 

Gene Transcripts significantly down-regulated in BCC compared to normal skin specimens (≥1.2 fold; ≥100; p \< 0.05).

  **probe set**   **gene**                                                                       **Accession**   **fold change**   **Difference**   **P value**
  --------------- ------------------------------------------------------------------------------ --------------- ----------------- ---------------- -------------
  239929_at       hypothetical protein FLJ32569                                                  AA918425        -28.24            -3433.29         0.014118
  208962_s\_at    fatty acid desaturase 1                                                        BE540552        -20.2             -3188.7          0.045399
  229476_s\_at    thyroid hormone responsive (SPOT14 homolog, rat)                               AW272342        -17.15            -4660.08         0.034919
  207275_s\_at    acyl-CoA synthetase long-chain family member 1                                 NM_001995       -15.11            -1865.7          0.039975
  206799_at       secretoglobin, family 1D, member 2                                             NM_006551       -14.97            -1291.31         0.042413
  234513_at       elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like   AF292387        -13.28            -670.81          0.022544
  221561_at       sterol O-acyltransferase (acyl-Coenzyme A: cholesterol acyltransferase) 1      L21934          -12.23            -998.57          0.008422
  206714_at       arachidonate 15-lipoxygenase, second type                                      NM_001141       -11.45            -3891.76         0.045644
  214240_at       galanin                                                                        AL556409        -11.12            -1590.25         0.015802
  244661_at       gb:AA946876/DB_XREF=gi:3110271/DB_XREF=oq53c11.s1/CLONE=                       AA946876        -10.56            -399.74          0.017168
  244780_at       sphingosine-1-phosphate phosphotase 2                                          AI800110        -9.79             -351.6           0.024348
  201625_s\_at    insulin induced gene 1                                                         BE300521        -9.72             -1591.34         0.030044
  231810_at       BRI3 binding protein                                                           BG106919        -8.9              -877.2           0.021503
  1565162_s\_at   microsomal glutathione S-transferase 1                                         D16947          -8.6              -1071.37         0.030259
  238121_at       Transcribed locus, weakly similar to XP_341569.1 similar to ORF4               AI473796        -8.29             -445.99          0.042733
  211056_s\_at    steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta    BC006373        -7.88             -1432.56         0.032165
  229957_at       Branched chain keto acid dehydrogenase E1, alpha polypeptide                   BF446281        -7.63             -1214.3          0.025272
  204675_at       steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta    NM_001047       -7.35             -2832.7          0.027894
  233030_at       adiponutrin                                                                    AK025665        -7.35             -1220.35         0.031698
  231736_x\_at    microsomal glutathione S-transferase 1                                         NM_020300       -7.28             -2497.22         0.031804
  205029_s\_at    fatty acid binding protein 7, brain                                            NM_001446       -7.24             -524.52          0.021739
  201627_s\_at    insulin induced gene 1                                                         NM_005542       -7.23             -627.89          0.049971
  209522_s\_at    carnitine acetyltransferase                                                    BC000723        -7.23             -2039.08         0.020824
  226064_s\_at    diacylglycerol O-acyltransferase homolog 2 (mouse)                             AW469523        -7.1              -2291.54         0.032748
  231156_at       gb:AW242782/DB_XREF=gi:6576459/DB_XREF=xm89g06.x1/CLONE                        AW242782        -7.09             -339.26          0.045195
  223184_s\_at    1-acylglycerol-3-phosphate O-acyltransferase 3                                 BC004219        -7.01             -1374.94         0.045149
  232428_at       monoacylglycerol O-acyltransferase 2                                           AK000245        -6.97             -182.68          0.038707
  1558846_at      Pancreatic lipase-related protein 3                                            AL833418        -6.71             -2007.72         0.044402
  205030_at       fatty acid binding protein 7, brain                                            NM_001446       -6.41             -1864.48         0.021392
  205843_x\_at    carnitine acetyltransferase                                                    NM_000755       -6.41             -1166.98         0.020573
  224435_at       chromosome 10 open reading frame 58///chromosome 10 open reading               BC005871        -6.37             -1905.14         0.007356
  1560507_at      Diacylglycerol O-acyltransferase 2-like 3                                      BC039181        -6.28             -441.54          0.028259
  215726_s\_at    cytochrome b-5                                                                 M22976          -5.95             -3458.82         0.02416
  220431_at       DESC1 protein                                                                  NM_014058       -5.94             -112.38          0.029175
  225716_at       gb:AI357639/DB_XREF=gi:4109260/DB_XREF=qy15b05.x1/CLONE=                       AI357639        -5.94             -1718.34         0.01598
  204388_s\_at    monoamine oxidase A                                                            NM_000240       -5.89             -362.75          0.037779
  45288_at        abhydrolase domain containing 6                                                AA209239        -5.83             -698.25          0.020361
  218804_at       transmembrane protein 16A                                                      NM_018043       -5.75             -234.79          0.045057
  228479_at       gb:AI094180/DB_XREF=gi:3433156/DB_XREF=qa29b09.s1/CLONE=                       AI094180        -5.7              -1191.04         0.029615
  227804_at       hypothetical protein BC014072                                                  BE328850        -5.62             -363.64          0.043913
  234312_s\_at    acetyl-Coenzyme A synthetase 2 (ADP forming)                                   AK000162        -5.54             -1297.68         0.044265
  1562528_at      RAR-related orphan receptor A                                                  BC040965        -5.48             -120.02          0.025055
  208964_s\_at    fatty acid desaturase 1                                                        AL512760        -5.46             -3305.87         0.025757
  213693_s\_at    gb:AI610869/DB_XREF=gi:4620036/DB_XREF=tp21e08.x1/CLONE=                       AI610869        -5.43             -1427.55         0.023253
  237507_at       keratin 6 irs3                                                                 AI333069        -5.43             -271.6           0.008082
  204389_at       monoamine oxidase A                                                            NM_000240       -5.4              -180.28          0.0359
  214598_at       claudin 8                                                                      AL049977        -5.27             -370.2           0.01827
  201963_at       acyl-CoA synthetase long-chain family member 1                                 NM_021122       -5.19             -4459.79         0.010049
  218434_s\_at    acetoacetyl-CoA synthetase                                                     NM_023928       -5.17             -1842.1          0.004574
  221552_at       abhydrolase domain containing 6                                                BC001698        -5.06             -402.38          0.024809

Top 50 transcripts -- based on fold difference are shown (complete list is supplied as supplementary material).

###### 

GOstat analysis of biological processes.

  **GO Number**   **Observed Transcripts**   **Total Transcripts**   **GO Category**                                               **P value**
  --------------- -------------------------- ----------------------- ------------------------------------------------------------- -------------
  GO:0019222      293                        3309                    regulation of metabolism                                      1.24E-33
  GO:0006351      264                        2884                    transcription, DNA-dependent                                  5.41E-33
  GO:0006355      258                        2809                    regulation of transcription, DNA-dependent                    1.61E-32
  GO:0006357      55                         280                     regulation of transcription from RNA polymerase II promoter   5.40E-31
  GO:0008134      57                         346                     transcription factor binding                                  6.86E-24
  GO:0016563      45                         250                     transcriptional activator activity                            9.36E-22
  GO:0003677      240                        2906                    DNA binding                                                   1.54E-21
  GO:0003712      44                         276                     transcription cofactor activity                               3.54E-17
  GO:0007049      89                         807                     cell cycle                                                    9.89E-17
  GO:0016043      163                        1986                    cell organization and biogenesis                              8.78E-14
  GO:0003713      30                         171                     transcription coactivator activity                            1.08E-13
  GO:0008283      65                         560                     cell proliferation                                            1.17E-13
  GO:0051726      61                         522                     regulation of cell cycle                                      5.62E-13
  GO:0000074      60                         518                     regulation of progression through cell cycle                  1.51E-12
  GO:0005578      48                         377                     extracellular matrix                                          3.00E-12
  GO:0007155      77                         874                     cell adhesion                                                 5.65E-08
  GO:0008380      24                         173                     RNA splicing                                                  3.60E-07
  GO:0016477      18                         112                     cell migration                                                5.56E-07
  GO:0016055      19                         128                     Wnt receptor signaling pathway                                2.09E-06
  GO:0008219      60                         675                     cell death                                                    2.29E-06
  GO:0007167      25                         207                     enzyme linked receptor protein signaling pathway              1.13E-05
  GO:0030154      50                         550                     cell differentiation                                          1.13E-05
  GO:0005604      13                         62                      basement membrane                                             7.37E-05
  GO:0051301      22                         190                     cell division                                                 0.000156
  GO:0042981      38                         418                     regulation of apoptosis                                       0.000269
  GO:0000904      11                         66                      cellular morphogenesis during differentiation                 0.00262
  GO:0043123      13                         91                      positive regulation of I-kappaB kinase/NF-kappaB cascade      0.00344
  GO:0005581      11                         73                      collagen                                                      0.00597
  GO:0030198      8                          43                      extracellular matrix organization and biogenesis              0.00788
  GO:0007154      247                        4475                    cell communication                                            0.0122
  GO:0005583      4                          11                      fibrillar collagen                                            0.0125
  GO:0008286      5                          20                      insulin receptor signaling pathway                            0.0182
  GO:0016049      17                         174                     cell growth                                                   0.019
  GO:0008361      17                         174                     regulation of cell size                                       0.019
  GO:0005610      2                          2                       laminin-5                                                     0.0205
  GO:0008083      20                         221                     growth factor activity                                        0.0232
  GO:0005588      2                          3                       collagen type V                                               0.0477

Biological processes that are significantly enriched in our set of 2,108 transcripts found to be significantly up-regulated in BCC compared to normal skin specimens. Shown here is a sub-set of 37 representative significant GO annotations.

###### 

GOstat analysis of biological processes.

  **GO Number**   **Observed Transcripts**   **Total Transcripts**   **GO Category**                                       **P value**
  --------------- -------------------------- ----------------------- ----------------------------------------------------- -------------
  GO:0006119      36                         138                     oxidative phosphorylation                             2.77E-34
  GO:0006091      120                        1003                    generation of precursor metabolites and energy        3.75E-33
  GO:0016491      123                        1170                    oxidoreductase activity                               7.47E-26
  GO:0006732      44                         269                     coenzyme metabolism                                   5.71E-21
  GO:0006629      86                         765                     lipid metabolism                                      1.17E-20
  GO:0003954      24                         62                      NADH dehydrogenase activity                           8.07E-16
  GO:0043037      40                         280                     translation                                           4.26E-15
  GO:0016651      27                         99                      oxidoreductase activity, acting on NADH or NADPH      1.63E-13
  GO:0016126      16                         31                      sterol biosynthesis                                   5.82E-13
  GO:0008135      29                         185                     translation factor activity, nucleic acid binding     8.99E-13
  GO:0045045      30                         217                     secretory pathway                                     1.31E-10
  GO:0006099      14                         45                      tricarboxylic acid cycle                              5.49E-08
  GO:0046356      14                         45                      acetyl-CoA catabolism                                 5.49E-08
  GO:0006511      25                         201                     ubiquitin-dependent protein catabolism                2.83E-07
  GO:0006413      17                         84                      translational initiation                              1.20E-06
  GO:0048193      19                         108                     Golgi vesicle transport                               2.00E-06
  GO:0006412      87                         1228                    protein biosynthesis                                  5.29E-06
  GO:0008289      35                         380                     lipid binding                                         2.46E-05
  GO:0006445      15                         92                      regulation of translation                             7.85E-05
  GO:0006888      13                         72                      ER to Golgi vesicle-mediated transport                9.90E-05
  GO:0006915      49                         644                     apoptosis                                             0.000214
  GO:0008415      20                         190                     acyltransferase activity                              0.000313
  GO:0006944      7                          32                      membrane fusion                                       0.00289
  GO:0016281      4                          9                       eukaryotic translation initiation factor 4F complex   0.00313
  GO:0006984      4                          9                       ER-nuclear signaling pathway                          0.00313
  GO:0044242      7                          33                      cellular lipid catabolism                             0.00349
  GO:0030503      3                          5                       regulation of cell redox homeostasis                  0.00611
  GO:0007050      11                         85                      cell cycle arrest                                     0.00717
  GO:0016282      5                          27                      eukaryotic 43S preinitiation complex                  0.0303

Biological processes that are significantly enriched in our set of 1,813 transcripts found to be significantly down-regulated in BCC compared to normal skin specimens. Shown here is a sub-set of 29 representative significant GO annotations.

![Scatter Plot of the 3,921 gene transcripts identified as significantly differentially expressed (by ≥1.2 fold; ≥100 difference in expression intensity; P \< 0.05) between BCC and normal skin specimens. Transcripts significantly up-regulated are shown in red; those down-regulated are shown as green.](1476-4598-5-74-1){#F1}

In order to identify specimen similarity/diversity in our group of 25 skin specimens, condition tree clustering (using Pearson\'s correlation coefficient as similarity metric) and principal component analysis (PCA) were performed using GeneSpring software. As indicated in Fig. [2(A)](#F2){ref-type="fig"}, while Pearson\'s correlation coefficient does not suggest a significant difference (*i.e*. no values \<0.9) between the 25 specimens analysed, the 5 normal specimens form a discrete cluster in relation to the BCC specimens. (A similar clustering pattern was obtained when Spearman\'s correlation coefficient was investigated). Two of the BCC specimens, T19 and T22, are apparently different (but not significantly different) to the other 18 BCCs. While the 3\'/M ratios were greater than expected (at least in comparison to cell line data) for these specimens, this was also the case for BCC26, T16, T24, T25 and T28, which did not group with T19 and T22. The higher scaling factor resulting from analysis of T19 and T22, compared to all other specimens, may be responsible for/contribute to their apparently somewhat different behaviour as represented on the condition tree. For the purpose of investigating the effects of T19 and T22 on the overall dataset, a re-analysis was performed excluding data relating to those specimens. This resulted in a reduction from 3,921 (*i.e*. 7.17%) to 3,865 (7.06%) of significantly differentially expressed transcripts between BCC and normal specimens, indicating that the vast majority of these transcripts are unbiased by the slightly different behaviour of T19 and T22 compared to all other BCCs (as described above).

![**(A)**Condition tree distribution of the 20 BCC (*red*) and 5 normal skin (*yellow*) specimens (following dCHIP normalisation, similarity measure, Pearson\'s correlation, clustering algorithm, average linkage). Expression values ≥100 are indicated in red; ≥50 to \<100 are indicated in black, and 0 to \<50 are indicated in green. **(B)**Two-dimensional principal component analysis (PCA) plot where red dots represent BCC specimens and yellow dots represent normal skin specimens indicating that while the normal specimens form a loose cluster (*solid line oval*), the BCC specimens are more \"scattered\" and varied (*broken line oval*). The first principal component expression value is 29.73%; the second component expression value is 12.05%.](1476-4598-5-74-2){#F2}

To further identify the relatedness of the BCC samples to each other, we performed principal components analysis \[[@B17]\] on the entire data set. PCA was carried out on log-transformed data, using mean centering and scaling. As can be seen in Fig. [2(B)](#F2){ref-type="fig"}, while our PCA analysis has divided the specimens into two groups, the results indicate that the BCC sub-group is much more varied than the normal skin group and that the BCC and normal skin specimens do not differ greatly.

Support Vector Machine analysis \[[@B18]\] is a machine learning classification approach which is suitable for application to the dimensionality of microarray data. It operates by examining the expression information of a set of data points whose classification is known (referred to as the \"training set\"), from which a defined number of classification predictor genes are identified. This predictor genelist can then be applied to a separate set of genes which are known not to be members of the functional class (referred to as the \"test set\"). The predictor genelist is user-defined, so it is more beneficial to the user for validation if a smaller number of genes comprise the predictor list.

For the purposes of this study, we carried out SVM analysis repeatedly on the tumour vs. normal dataset, in order to identify the lowest number of probesets that discriminated 100% of the time between the two classifications. The gene selection method used was Fisher\'s Exact Test, the kernel function was Polynomial Dot Product (Order 1) with zero Diagonal Scaling Factor. A minimum number of six identifiers, shown in Table [6](#T6){ref-type="table"}, were required for 100% classification of every specimen as either tumour or normal in origin. Attempts to further prioritise these genes resulted in a decrease in the efficiency of the classification, as further analysis aimed at classifying the specimens using less than six transcripts resulted in the mis-classification of normal specimen N5 as a BCC specimen.

###### 

Transcripts identified using Support Vector Machine as suitable, as a group, for 100% classification of BCC from normal skin.

  **I.D.**       **Gene Transcript**
  -------------- ---------------------------------------------------------------------------------------------
  1553718_at     zinc finger protein 548
  201413_at      hydroxysteroid (17-beta) dehydrogenase 4
  225677_at      B-cell receptor-associated protein 29
  223184_s\_at   1-acylglycerol-3-phosphate O-acyltransferase 3
  203878_s\_at   matrix metalloproteinase 11 (stromelysin 3)
  225716_at      Full-length cDNA clone CS0DK008YI09 of HeLa cells Cot 25-normalized of Homo sapiens (human)

qPCR Validation of Microarray Data
----------------------------------

Quantitative-PCR (qPCR) analysis for 10 potential endogenous controls was performed on a random selection of four BCC and four normal skin specimens, to select a suitable endogenous control(s) amplifiable in all specimens and where levels of expression did not differ greatly between specimens being analysed. All 10 transcripts studied were found to be expressed in all specimens analysed and, as indicated in Fig. 3 \[[Additional File 3](#S3){ref-type="supplementary-material"}\], expression levels and standard deviation results suggested that the 10 transcripts are likely to be of similar suitability as endogenous controls. Two controls, β-actin and GAPDH, were subsequently selected for amplification in all specimens, in parallel with a selection of 5 target transcripts of interest. The relative expression levels of *PTCH1*, *gli2, Frizzled D2, basonuclin 2, and chromagranin A*were analysed by qPCR. As indicated in Table [7](#T7){ref-type="table"}, while the fold differences detected by microarray and qPCR methods differed to some extent, the trend (*i.e*. absent/low expression in normal skin and induced/increased expression in BCCs) was always found.

###### 

Validation of microarray data by qPCR

  **Transcript**     **I.D.**    **Microarray^1^Mean Expression Levels in Normal Skin**   **Microarray^1^Mean Expression Levels in BCC**   **Microarray (*fold*)^2^**   ***qPCR*^3^Mean Expression Levels in Normal Skin**   ***qPCR*^3^Mean Expression Levels in BCC**   ***qPCR*(*fold*)^2^**
  ------------------ ----------- -------------------------------------------------------- ------------------------------------------------ ---------------------------- ---------------------------------------------------- -------------------------------------------- -----------------------
  *chromagranin A*   NM_001275   19.31                                                    2516.41                                          130.34                       0.000                                                1.083                                        P
  *gli2*             NM_030379   23.51                                                    173.73                                           7.39                         0.000                                                1.662                                        P
  *PTCH1*            BG054916    229.86                                                   2375.81                                          10.34                        0.025                                                1.455                                        58.2
  *basonuclin 2*     NM_017637   204.42                                                   1827.2                                           8.94                         0.077                                                1.034                                        13.4
  *frizzled 2*       L37882      54.93                                                    490.8                                            8.94                         0.047                                                6.505                                        138.4

*Note*: ^1^= Expression levels, Affymetrix arbitrary units; ^2^= fold increased expression in BCC compared to normal; ^3^= following normalisation of data on mean of β-actin + GAPDH expression and calibrating to a pooled skin specimen control (as described in Materials and Methods); P = induced in BCC, while undetected in normal skin

Discussion
==========

Basal cell carcinoma (BCC), the most common skin cancer in humans, is locally aggressive and relentlessly invasive, but generally does not metastasise \[[@B5],[@B19]\]. Despite this, studies aimed at investigating the molecular mechanisms associated with -- possibly responsible for -- BCCs, have been very limited. In 2005, Howell *et al*. \[[@B7]\] reported findings from their analysis of 1,718 transcripts in BCC specimens, using cDNA microarrays. While this study produced very interesting results, as explained by the authors, numbers of transcripts potentially important in BCC -- such as *PTCH1*and *SMO*-- were not represented on their microarray; limiting their study considerably. Here we have successfully analysed gene expression of BCCs, compared to normal skin, using whole genome microarrays and following extensive analysis of our data, in addition to confirming previous findings, we have identified a number of novel potential biomarkers/therapeutic targets for this disease.

Comparison of our results with those generated by Howell *et al*. \[[@B7]\] indicated a relatively high level of agreement between these two studies. Many of the transcripts identified by Howell *et al*. as up-regulated in BCC compared to normal skin were also found to be up-regulated in BCC in our study. Examples of these include collagens (*type V, alpha 1 & alpha 2; type IV alpha 1 & 2; type VII alpha 1*), *topoisomerase II*α, *tumour-associated calcium signal transducer 1*, *profilin 2*, *calretinin*, *syndecan 2*, and *v-myc*. Similarly, a high concordance between these two studies was found for transcripts down-regulated in BCCs compared to normal specimens; examples of which include *cystatin B*, *acetyl-Coenzyme acyltransferase 1, 3-hydroxy-3-methylglutaryl-Coenzyme A reductase*, *glutaredoxin*, *amyloid*β *(A4) precursor-like protein*, and *cytochrome b-5*. However, in the case of a limited number of differentially expressed transcripts, the direction of change in expression in BCC compared to normal skin was not in agreement. Examples include *ADP-ribosylation factor 3*(down-regulated by 1.67 fold in our study \[expression values 941.51 vs. 563.45\], but up-regulation reported by Howell *et al*. \[[@B7]\] and *glia maturation factor*β (1.42 up-regulated in our analysis \[expression values 969.02 vs. 1,377.23\], but reported by Howell *et al*. as down-regulated). While the reasons for these limited number of discrepencies is unknown, it may be due to different splice variants of these transcripts being detected by cDNA compared to oligo microarrays. It is worth noting that the results that differed between our study and that of Howell *et al*. were generally transcripts that we found to be \<2 fold differentially expressed between BCC and normal skin. Unfortunately, as fold changes observed by Howell *et al*. \[[@B7]\] were not reported in their manuscript and information is not publicly available on transcripts that were present on their microarray, but were not significantly changed, further comparisons between these studies cannot be performed.

The development of BCC is known to be associated with dys-regulation of the hedgehog and Wnt pathways \[[@B2],[@B20]\]. Lack of expression and/or suppressed activation of patched homologue 1 (PTCH1), a tumour suppressor gene that forms part of the hedgehog signaling network \[[@B21]\], has been reported to be fundamental to the development of BCC \[[@B22]\]. Disruption of this tumour suppressor gene results in up-regulated cell proliferation \[[@B6]\]. The accepted mechanism of PTCH1\'s action is via its binding to another transmembrane molecule, smoothed (SMO), thus suppressing intracellular signaling. Following binding of sonic hedgehog (shh) to PTCH1, this suppressor activity is, however, quenched, resulting in uninterrupted signal transduction by SMO, *via*GLI transcription factors, and subsequent constitutive activation of target genes, including members of the Wnt pathway \[[@B23]\] and PTCH1, itself \[[@B21]\]. From our analysis of BCC compared to normal skin tissue, while we found no significant changes in *shh*expression levels, we report an approximately 11 fold increased expression of *PTCH1*\[expression values 25.65 vs. 271.62\], and also increased expression of *gli2*(7.39 fold; P = 0.00009) \[expression values 23.52 vs. 173.73\], respectively. The induced/increased expression of *PTCH1*and *gli2*found by microarray analysis was confirmed by qPCR analysis of all specimens (see Table [7](#T7){ref-type="table"}). It is important to note that the likely reason for the difference in fold expression detected by microarray and qPCR methods is due to their differing baseline sensitivity. Low expression levels detected by microarrays -- *e.g*. *gli2*in normal skin -- resulting in large fold differences are considered as induction from absent in normal skin compared to present in BCC specimens, when analysed by qPCR. However, although *PTCH1*mRNA levels have previously been reported as enhanced in nodular BCC but undetectable in superficial BCC \[[@B24]\], here we report *PTCH1*to be detectable in both of these histological types of BCC, with no significant difference in their respective expression values (t-test: p = 0.637).

While the increased expression of *gli2*detected in BCCs compared to normal skin may be expected and associated with the development/presence of BCC, the lack of tumour suppressor activity by PTCH1 -- despite its increased mRNA levels -- may be due to lack of expression of its corresponding protein and/or lack of binding to *SMO*(levels of which were not significantly different between BCC and normal skin). As PTCH1 may shuttle between the cell membrane and endocytotic vesicles in response to active hedgehog ligand, it is obvious that not only its mRNA expression, but also its protein expression (at the relevant location, binding of SMO, *etc*.) is necessary to exert its tumour suppressor activity \[[@B21]\]. Furthermore, as loss-of-function mutations of PTCH1 have been identified in 30--40% of sporadic cases of BCC, it may be that the mRNA over-expressed in the BCCs is not coding for a functional protein.

Wnt signaling may be able to regulate a number of the aspects of the biology of tumour cells and thus contribute in several ways to the tumour phenotypes. The strongest link is to the control of proliferation. Knockouts of Wnt signal transduction components, including Wnt5A, can result in proliferative failure \[[@B25]\] while up-regulation of *Wnt5A*mRNA expression been associated with a range of cancer types, including breast, lung, prostate and malignant melanomas \[[@B26],[@B27]\]. In our study, the involvement of Wnt signaling pathway in BCC is suggested by the significantly increased expression of a number of Wnt family members. These include *Wnt5A*(3.35 fold; P = 0.00003) \[expression values 403.73 vs. 1,353.71\], -- in agreement with a study by Saldanha *et al*. \[[@B19]\] where Wnt5A levels were increased in BCCs compared to surrounding skin -- and *Wnt6*(4.86 fold; P = 0.00002) \[expression values 59.7 vs. 290.26\]. Increased levels of Wnt ligand binding receptors, *Frizzled D2*(8.94 fold; P = 0.000033) \[expression values 54.93 vs. 490.8\], *D7*(2.31 fold; P = 0.000085) \[expression values 276.23 vs. 638.34\], and *D8*(5.89 fold; P = 0.000055) \[expression values 44.44 vs. 261.74\], and decreased levels of *D4*(-2.78 fold; P = 0.02) \[expression values 598.41 vs. 215.2\], were also found. The increased expression of *Frizzled D2*in BCC compared to normal skin was confirmed by qPCR.

In the \"canonical\" Wnt signaling pathway, secreted ligands bind to Frizzled receptors and regulate the stability of β-catenin. (Given the large number of mammalian Frizzleds and Wnts, considerable ligand-receptor specificity might be expected; however, redundancy of function seems to be the rule \[[@B25]\]). The subsequent accumulation of β-catenin -- the central player in the Wnt pathway \[[@B28]\] -- in the nucleus, results in its participation in transcriptionally active complexes with members of the LEF/TCF family of transcription factors \[[@B29]\]. While we did not find levels of β-catenin to be significantly different between BCC and normal skin, decreased (-2.1 fold; P = 0.006) \[expression values 2,090.09 vs. 992.89\], levels of *CTNNBIP1*, an [i]{.ul}nhibitor of β-[ca]{.ul}tenin and [T]{.ul}CF-4 (ICAT) which would normally prevent β-catenin binding to LEF transcription factors \[[@B30]-[@B32]\] and increased levels of *LEF1*transcripts (3.42 fold; P = 0.000001) \[expression values 513.06 vs. 1,752.32\], were found. Levels of *Jun*(2.34 fold; P = 0.00006) \[expression values 875.92 vs. 2,052.07\], another transcription factor involved in the Wnt pathway \[[@B33]\], were also found to be increased in BCCs compared to normal skin. Differential expression of other transcription factors associated with cancer has also been found in this study. These include *CHES1*(*checkpoint suppressor 1*) which is apparently involved in repressing expression of genes important for tumorigenesis \[[@B34]\]. *CHES1*mRNA has been reported as down-regulated in oral squamous cell carcinoma \[[@B35]\] and in hepatocellular carcinoma \[[@B36]\]. Here we found *CHES1*mRNA levels to be significantly (-2.03 fold; P = 0.045) \[expression values 920.32 vs. 452.95\], down-regulated in BCC compared to normal skin. Not unexpectedly, mRNAs encoding proteins involved in inducing apoptosis were also found to be down-regulated. These include *CIDE*\[[@B37]\] and *CARD15*\[[@B38]\] which are 4.18 fold (P = 0.029) \[expression values 415.5 vs. 99.41\] and 2.31 fold (P = 0.031) \[expression values 313.08 vs. 135.42\], down-regulated in BCC compared to normal skin.

Using support vector machine analysis we have identified 6 transcripts that, as a group, enable the accurate classification of all 25 specimens as BCC or normal skin. These include *matrix metalloproteinase 11/mmp11*(previously associated with the presence of other cancer types, including oral \[[@B39],[@B40]\], lung \[[@B41]\] and breast \[[@B42]\]); *hydroxysteroid (17-beta) dehydrogenase 4/hsd17b4*(changes in expression of which have been associated with breast cancer (\[[@B43]\]); *B-cell receptor-associated protein 29/bap29*(a member of the B cell receptor-associated family of proteins \[[@B44]-[@B46]\]); *1-acylglycerol-3-phosphate O-acyltransferase 3/agpat3*(which catalyses the acylation of lysophosphatidic acid to form phosphatidic acid, the precursor of all glycerolipids \[[@B47]\]); as well as *zinc finger protein 548*and *full-length cDNA clone CS0DK008YI09 of HeLa cells Cot 25-normalized of homo sapiens*, on which no literature has previously been published. Future studies involving the co-analysis of this group of 6 transcripts in larger cohort of BCC and normal skin specimens should enable validation of their diagnostic relevance.

Molecular events responsible for the quite unique invasive, but non-metastatic, nature of BCCs are not known. However, it is interesting to note that expression of certain genes believed to be involved in malignant invasion and metastasis of another form of skin cancer, *i.e*. malignant melanoma, apparently differ in their expression patterns in BCCs. *AP-2*transcription factor is not expressed in malignant melanoma cells \[[@B48]\], but it is significantly up-regulated (by 10.7 fold) \[expression values 227.05 vs. 2,423.26\], in BCC specimens compared to normal skin. Conversely, increased expression of *EGF-R*is associated with melanomas metastasis \[[@B48]\], but its expression is down-regulated (by approximately 1.2 fold) \[expression values 76.91 vs. 62.78\], in BCCs. Unlike BCCs, breast cancers frequently metastasise. Interestingly, in our microarray study of 104 breast tumours and normal breast tissue (*manuscript in preparation*) we identified changes in expression patterns of syndecan adhesion receptors (*for review*: see \[[@B49]\]) *i.e*. *syndecan 1*is up-regulated, and *syndecan 2*is down-regulated, in breast tumours compared to normal breast tissue. In this study of non-metastatic BCCs, we found *syndecan 1*to be approximately 1.6 fold down-regulated \[expression values 3,488.91 vs. 2,124.43\], and *syndecan 2*to be approximately 3 fold \[expression values 160.21 vs. 559.84\] up-regulated compared to levels in normal skin tissue. Furthermore, ankyrin (encoding membrane-associated cytoskeletal proteins) binding to membrane molecules has been suggested as necessary for cell adhesion, migration and tumour metastasis \[[@B50]\]. In our breast cancer study we found *ankyrin 3*expression levels to be up-regulated compared to normal tissue, while here we report *ankyrin 3*levels to be down-regulated (approximately 1.6 fold) \[expression values 350.02 vs. 224.48\], in BCC compared to normal tissue. While functional studies would be required to determine a causative/direct, rather than an associative, role for transcripts such as *AP-2*, *EGF-R*, *syndecan 1*&*2*, and *ankyrin 3*in controlling metastasis, the results from this study suggest that expression of the mRNAs may be, in some way, involved in this process.

Differential expression, between BCC and normal skin, of many transcripts not previous associated with the presence of BCC was also found during the course of our study. Basonuclin (now termed Basonuclin 1; was first discovered in cultured human epidermal cells \[[@B51]\]) and the more recently discovered basonuclin 2 \[[@B52]\] are zinc finger proteins. Basonuclin 1 is expressed at high levels in proliferating keratinocytes of stratified squamous epithelium. During terminal differentiation of squamous epithelium, *basonuclin*mRNA and protein disappear from the suprabasal cells \[[@B53],[@B54]\]. In normal cultured human keratinocytes, *basonuclin 1*is the predominant transcript -- with expression levels approximately 10 fold that of *basonuclin 2*\[[@B52]\]. In this study we found that *basonuclin 1*levels did not differ significantly between BCC and normal skin, although a previous study of 3 BCC and 2 normal skin specimens indicated increased expression of *basonuclin 1*in BCC, dependent on Gli protein expression \[[@B55]\]. In contrast, we report *basonuclin 2*levels to be significantly increased in BCCs. This finding was observed with all 4 *basonuclin 2*probe sets present on the microarray, indicating a 6.7--9.6 fold increase level (P \< 0.00005) of expression \[greatest change in expression values being 85.63 vs. 828.01\], in BCC. This increased expression of *basonuclin 2*in BCC compared to normal skin was confirmed by qPCR analysis. This, we believe, is the first study indicating an association between expression of *basonuclin 2*and BCC.

ABCC12/mrp9, identified in 2001 \[[@B56]\] is one of a super-family of 9 ATP-binding cassette (ABC) multiple drug resistant proteins \[[@B57]\]. *Mrp9*encodes an approximately 100 kDa protein detectable in breast cancer, normal breast tissue and testis, while an alternative *mrp9*transcript -- encoding an approximately 25 kDa protein -- has been detected in normal brain, skeletal muscle and ovary tissues. Due to the differential levels of expression of *mrp9*transcripts in breast tumour and normal tissue, MRP9 has been proposed as an immunotherapy target for breast cancer \[[@B58]\]. The functional relevance of our observation of approximately 8.7 fold greater levels of *mrp9*\[expression values 21.12 vs. 184.71\] in BCC compared to normal skin has yet to be determined; its presence is unlikely to be involvement in drug resistance, as all of the BCCs included in this study were chemotherapy-naive (indeed, except in a limited number of advanced cases of BCC, chemotherapy is not used as a therapy for this disease. In these exceptional cases, excellent response rates have been reported with cisplatin in combination with either 5-fluorouracil or doxorubicin \[[@B59]\]). However, as for breast cancer, *mrp9*mRNA may be useful as a member of a panel of BCC biomarkers or as an immunotherapy.

Chromagranin A (ChgA; parathyroid secretory protein 1) is an established tissue marker associated with neuroendocrine differentiation -- and indicative of outcome -- in non-small cell lung carcinoma \[[@B60]\]. Increased levels of ChgA in serum have been associated with poor prognosis/shortened survival for prostate cancer patients \[[@B61]\]. ChgA protein levels have been proposed to assist in the diagnosis of Merkel cell carcinoma patients who may benefit from oncological therapy \[[@B62]-[@B64]\]. Although described as relatively uncommon -- using analysis of markers including ChgA -- neuroendocrine differentiation in BCC has been reported \[[@B65]\]. In this study we have found *ChgA*levels to be significantly (130.3 fold; P = 0.000001) \[expression values 19.31 vs. 2,516.41\], up-regulated in BCCs compared to extremely low levels in normal skin specimens. This is in agreement with the observation of ChgA protein detectable in 55% (11/20) BCC specimens \[[@B66]\]. By qPCR analysis, *ChgA*was undetected in normal skin but was present in BCC specimens. Interestingly, other neuroendocrine markers, including *SNAP-25*(3.24 fold; P = 0.008) \[expression values 40.17 vs. 130.25\] and *neuroendocrine protein 1/7B2 protein*(3.48 fold; P = 0.0001) \[expression values 46.38 vs. 161.44\], were also increased in the BCC specimens. These results indicate *ChgA*to be a potentially very useful marker for BCC.

In this study we present the first whole genome expression microarray analysis of skin cancer, aimed at investigating the molecular profile of BCC in comparison to non-cancerous skin biopsies. This investigation has not only confirmed previous findings from analyses of limited numbers of transcripts, but it has also identified changes in expression of mRNAs that had never previously been associated with this disease. The results from this work are interesting and exciting, but it is necessary to recognise their preliminary nature. Further analyses, building on our findings, should include independent replication studies so that the true relevance of these findings may be realised.

Conclusion
==========

The success of this study indicates the feasibility and relevance of using whole genome microarrays to study BCC specimens. In addition to confirming previous findings, this work has increased our understanding of molecular differences between BCC and normal skin and has identified a number of novel potential biomarkers for BCC. Future studies including BCC tissue and normal skin tissue from the same individual, thus lowering inter-individual variability and ruling out genetic influences; analyses of age- and gender-matched cases; studies focusing on molecular profiling and comparisons of sub-types of BCC, with due consideration given to disease duration (as early tumours may have a different gene expression profile to prolonged tumours); as well as analysing BCCs that metastasise compared to those that do not, should further increase our understanding of this disease and assist in management of the individual BCC patients. Furthermore, as gene expression may be independent of protein levels, future confirmatory analysis at the protein level would complement these findings.

Materials
=========

Patient Characteristics
-----------------------

This study involved analysis of 20 BCC biopsies from both male and female patients aged between 47 years and 83 years (mean age = 65 +/- 11 years; median = 67 years) at the time of diagnosis. In order to gain an understanding of the most common types of BCC, we elected to include a range of BCC sub-types in this study, rather than to focus on any particular sub-type. For this reason, BCC sub-classifications included were nodular/micronodular, superficial and sclerosing. Tissue specimens from these twenty cases of BCC were procured at Blackrock Clinic and the Bons Secours Hospital, Dublin, examined macroscopically, immediately snap-frozen in liquid nitrogen, and were subsequently stored at -80°C until required for analysis. Five normal skin specimens (from consenting male and female volunteers of a similar age range who do not/never had skin cancer) were also included in these studies.

RNA Extraction
--------------

For RNA analyses, dissected tumours that had been snap-frozen in liquid nitrogen and then stored at -80°C until required were homogenised, on ice, in 1 ml TriReagent (Sigma; Poole, England) and total RNA was subsequently isolated according to the manufacturer\'s instructions. RNA quantity and purity were assessed at 260 nm and 280 nm using a Nanodrop (ND-1000; Labtech. International); an Agilent bioanalyser (Agilent 2100; Agilent Technologies) was used to assess RNA qualitatively after isolation and, subsequently, after biotin-labelling and after fragmentation.

100 ng of each specimen was amplified and labelled using the Affymetrix GeneChip Eukaryotic 2 Cycle Labelling Assays for Expression Analysis, (Affymetrix; 900494) according to the manufacturer\'s instructions <http://www.affymetrix.com/products/reagents/specific/cdna2.affx>. Gene expression was examined using whole genome microarrays (Affymetrix; U133 Plus 2.0; 900470).

Microarray hybridization
------------------------

Hybridisation solution (1 mol/l NaCl, 20 mmol/1 EDTA, 100 mmol/1 2-(N-morpholino) ethanesulfonic acid, and 0.01% Tween 20) was used to pre-hybridise Affymetrix; U133 Plus 2.0 oligonucleotide microarrays for 10 minutes at 45°C and 60 rpm. The pre-hybridisation solution was removed and replaced with 200 μl hybridisation solution containing 0.05 μg/μl fragmented cRNA. The arrays were hybridised for 16 hours at 45°C and 60 rpm. Arrays were subsequently washed (Affymetrix Fluidics Station 400) and stained with streptavidin-phycoerythrin (Stain Buffer, 2 mg/ml acetylated BSA and 10 μg/ml streptavidin R-phycoerythrin; Molecular Probes, Inc., Eugene, OR), and were scanned on an Affymetrix GCS GeneChip GeneArray scanner. Resulting data was analysed using GCOS, dCHIP, and GeneSpring (Agilent Technologies).

Normalisation and Filtering
---------------------------

Cel files obtained from the GCOS server were processed and normalized by dCHIP \[[@B67]\] algorithm. In this normalisation procedure, an array with median overall intensity is chosen as the baseline array against which other arrays are normalized at probe intensity level. Subsequently, a subset of PM probes, with small within-subset rank difference in the two arrays, serves as the basis for fitting a normalization curve. A filter was designed to include a fold change of at least 1.2 fold between normal and BCC specimens, a difference of at least 100 Affymetrix arbitrary units between normal and BCC average values, and a t-test between normal and BCC (with a p-value cut-off \<0.05).

Gene Ontology and Pathway Analysis Analysis
-------------------------------------------

In order to establish which gene ontologies (GO) are over-represented in our lists of 2,108 significantly up-regulated and 1,813 significantly down-regulated (in BCCs compared to normal skin) transcripts, we compared these to the list of all human genes from the EBI \[[@B68]\], using Gostat \[[@B69]\]. In brief, for all of the gene transcripts analysed, GOstat determines the associated annotated GO terms and all branches/splits on their connection path. The program then counts the number of appearances of each GO term for the gene transcripts in the list being analysed, as well as in the reference list. For each GO term, a Chi-squared p-value is calculated representing the probability that the observed numbers of counts could have resulted from randomly distributing this GO term between the tested and the reference lists. If the expected value for any analysis is \<5, the Chi-squared approximation is considered to be inaccurate. Genmapp \[[@B70]\] was used to identify pathways affected by the differentially-expressed genelist.

Real-time PCR (qPCR)
--------------------

Following priming with oligo (dT) at 65°C for 5 minutes, followed by 1 minute incubation on ice, cDNA was synthesised from 100 ng total RNA, using Superscript III RNase H- (with increased thermal stability; Invitrogen), RNase OUT Ribonuclease (active against RNase A, B and C; Invitrogen) and a cocktail of dNTPs, by incubating at 50°C for 1 hour, followed by 70°C for 15 minutes, in a 40 μl reaction volume. The cDNA (diluted 1:10), was amplified in 25 μl reactions, by qPCR, using an ABI 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA). Following evaluation of 11 potential endogenous controls in a random selection\* of 4 BCC and 4 normal specimens, this study involved evaluation, in all 20 BCC and 5 normal skin specimens, of 5 target transcripts normalised to 2 suitable endogenous controls -- β-actin and GAPDH -- and calibrated against a pooled cDNA of BCC and normal skin specimens, the relative quantity of which was set to 1. The temperature profile of all reactions was 50°C for 2 minutes 95°C for 10 minutes, 40 cycles of 95°C and 60°C for 1 minute. Individual specimens were analysed in triplicate. \[\* *Note*: these 4 BCC and normal specimens were analysed by microarrays with all of the other specimens included in this study\].
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BCC -- basal cell carcinoma; qPCR -- quantitative-polymerase chain reaction
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Table [2](#T2){ref-type="table"} \[[Additional File 1](#S1){ref-type="supplementary-material"}\]. Gene transcripts significantly up-regulated in BCC compared to normal skin specimens
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###### Additional File 2

Table [3](#T3){ref-type="table"} \[[Additional File 2](#S2){ref-type="supplementary-material"}\]. Gene transcripts significantly down-regulated in BCC compared to normal skin specimens
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###### Additional File 3

Figure 3 \[[Additional File 3](#S3){ref-type="supplementary-material"}\]. qPCR analysis of 10 transcripts in four BCC and four normal specimens as potential endogenous controls for analysis involving validation of microarray data in all specimens.
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